Vikas Sharma, Ph.D., brings more than 15 years of specialized experience in business and corporate development activities across the biotechnology and pharmaceutical landscapes. He has led multiple complex licensing deals and capital market transactions. Vikas is responsible for partnering of strategic assets including in-licensing and out-licensing, strategy, and operational activities.

Before joining QurAlis, Vikas was vice president and head of business development at BioXcel Therapeutics, where he was responsible for all business and corporate development activities. Prior to that, he played an instrumental role in leading licensing deals at MacroGenics with companies such as Incyte Corporation, Roche, and Janssen Pharmaceuticals. Prior to joining MacroGenics, Vikas served as the director, business development at Rexahn Pharmaceuticals where he led the due diligence and execution of licensing deals, M&A, as well as capital markets transactions. Previously, he served as manager, business development, for MedImmune (the global biologics business of AstraZeneca), where he executed multiple licensing transactions. In addition, he served in business development roles with increasing responsibilities at the Children’s Hospital of Philadelphia, Bradley Pharmaceuticals, and Advanced Bioadjuvant. He serves on the board of GO Therapeutics. Vikas earned a PhD and master’s degree in immunology from Rutgers University. He completed a bachelor’s degree and a master’s degree in microbiology from the University of Mumbai, India.